Novo Nordisk, the Danish pharmaceutical giant behind the blockbuster drugs Ozempic and Wegovy, has confirmed an IT security incident involving unauthorized access to a limited number of internal systems. Certain non-public data, including pseudonymized patient information from some clinical trials (such as patient IDs, trial participation, sex, year of birth, biomarkers, health/immunogenicity data, and lifestyle factors), was copied externally without authorization.
 |
| Source: Video Screenshot |
The company states that core business operations remain fully operational, though some internal IT systems were taken offline as a precaution. An investigation is underway with external cybersecurity experts, and relevant authorities have been contacted. Impacted parties are being notified as appropriate. Due to the pseudonymized nature of the data, Novo Nordisk assesses no immediate risks to patients and advises them only to remain vigilant and report anything unusual. No specific number of affected individuals or further details on the perpetrators have been disclosed yet.
This marks one of the latest high-profile data incidents in the pharmaceutical sector handling sensitive health information.
Danish pharmaceutical giant Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, said Thursday it had been hit been hit by a cybersecurity incident resulting in data being leaked.
The company said in a statement there had been “unauthorised access to a limited number of internal IT systems” and “certain non-public data” had been leaked.
Novo Nordisk said some of its internal IT systems had been taken offline but added: “Our core business operations are not impacted and remain up and running.”
Оригинальная статья: Novo Nordisk Cyber Incident: Data Leak from Clinical Trials – Ozempic Maker Responds on Planet Today 🚀
Автоматически переопубликовано из основного блога.
